Rare primary central nervous system tumors

Charlotte Dai Kubicky,1 Arjun Sahgal,2 Eric L. Chang,3 Simon S. Lo4
1Department of Radiation Medicine, Oregon Health Science University, Portland, OR, USA; 2Department of Radiation Oncology, Sunnybrook Health Science Centre, University of Toronto, ON, Canada; 3Department of Radiation Oncology, Keck School of Medicine and Norris Cancer Center at University of Southern California, Los Angeles, CA, USA; 4Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA

Abstract

There are close to 70,000 new cases of primary central nervous system tumors diagnosed annually in the United States. Meningiomas, gliomas, nerve sheath tumors and pituitary tumors account for 85% of them. There is abundant literature on these commonly occurring tumors but data from the literature on infrequently encountered tumors such as atypical teratoid/rhabdoid tumor, choroid plexus carcinoma, gangliogioma, hemangiopericytoma, and pleomorphic xanthoastrocytoma are limited. This review provides an overview of the clinicopathologic and therapeutic aspects of these rare primary central nervous system tumors.

Introduction

An estimated 69,720 new cases of primary central nervous system tumors are expected to be diagnosed in 2013 based on projection using the 2013 Central Brain Tumor Registry of the United States (CBTRUS) Statistical Report (www.cbtrus.org). Meningiomas, gliomas, nerve sheath tumors, and pituitary tumors together constitute more than 85% of all primary central nervous system tumors diagnosed in the US.1 There are some tumors which constitute less than 1% of all brain tumors. The purpose of this paper is to provide an overview of the clinical, pathologic and therapeutic aspects of some of the more commonly encountered rare primary brain tumors, including atypical teratoid/rhabdoid tumor, choroid plexus carcinoma, gangliogioma, hemangiopericytoma, and pleomorphic xanthoastrocytoma.

Atypical teratoid/rhabdoid tumor

Epidemiology

Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant embryonal tumor of the central nervous system, WHO grade IV. It contains sheets of rhabdoid cells, with additional components of small embryonal, mesenchymal and epithelial cells.5 AT/RT is the only pediatric malignancy that is uniquely associated with a tumor suppressor gene. In 1995, Rorke et al. first reported a link between AT/RT and chromosome 22.3 Further investigation identified the hSNF5/INI1 gene, which maps to chromosome 22q11.2. A homozygous deletion or mutation of the hSNF5/INI1 gene occurs in over 90% of AT/RTs. The hSNF5/INI1 gene encodes for a component of the SWI/SNF ATP-dependent chromatin-remodeling complex. This complex interacts with histone deacetylase and the retinoblastoma protein. It plays an important role at the Gl/S cell cycle checkpoint. The exact mechanism by which hSNF5/INI1 mediates tumorigenesis is not fully understood. Better understanding of the functionality of this gene can help elucidate the molecular pathways and identify potential therapeutic targets for AT/RT.5

Histopathology and molecular features

Atypical teratoid/rhabdoid tumor is a high grade malignant embryonal tumor of the central nervous system, WHO grade IV. It contains sheets of rhabdoid cells, with additional components of small embryonal, mesenchymal and epithelial cells.5 AT/RT is the only pediatric malignancy that is uniquely associated with a tumor suppressor gene. In 1995, Rorke et al. first reported a link between AT/RT and chromosome 22.3 Further investigation identified the hSNF5/INI1 gene, which maps to chromosome 22q11.2. A homozygous deletion or mutation of the hSNF5/INI1 gene occurs in over 90% of AT/RTs. The hSNF5/INI1 gene encodes for a component of the SWI/SNF ATP-dependent chromatin-remodeling complex. This complex interacts with histone deacetylase and the retinoblastoma protein. It plays an important role at the Gl/S cell cycle checkpoint. The exact mechanism by which hSNF5/INI1 mediates tumorigenesis is not fully understood. Better understanding of the functionality of this gene can help elucidate the molecular pathways and identify potential therapeutic targets for AT/RT.5

Imaging characteristics

A computed tomography (CT) scan is typically done during the initial work-up. AT/RTs are typically hyperdense on CT, and enhance intensely with contrast. Calcifications are uncommon. Cysts are more common in supratentorial lesions, and less common in infratentorial lesions. On T1-weighted MRI, tumors are isointense with frequent hyperintense foci consistent with intratumoral hemorrhage. Most tumors enhance strongly with gadolinium. On T2-weighted images, tumors are often heterogeneous reflecting a mixture of tumor, hemorrhage, necrosis and cysts.5

Clinical presentation

About 50% of AT/RTs arise in the posterior fossa. Up to 35-40% of patients have leptomeningeal disease at the time diagnosis. About 15% of patients have metastatic disease at presentation. Depending on the location, children may present with lethargy, nausea, vomiting, or cranial nerve palsies.5

Treatment options

Maximum safe resection is performed for most patients. Maximum safe resection can be either gross total or subtotal resections, based on what the neurosurgeon deems as the tumor volume that can be safely resected. It is estimated that total or near-total resection can be achieved in less than 1/3 of patients. Even though the extent of resection and its impact on survival has not been studied prospectively, retrospective analyses suggest improved survival with gross total resection.5,7 Adjuvant radiotherapy appears to have an impact on survival of AT/RT patients.6,8 Historically, for patients younger than 3 years, radiation was routinely withheld due to concern for long term neurocognitive toxicities. However, many chemotherapy regimens used in place of radiation, have not been shown to be effective. Therefore, the question of whether radiation should be given to children younger than 3 was raised.

Tekautz et al. reported a retrospective review of 31 patients treated at St. Jude Children’s Hospital.7 Twenty-two patients were younger than 3 years, and 9 were older than 3. All patients underwent surgery, 30 received adjuvant chemotherapy. The majority of the
children 3 years or older received adjuvant cranial spinal radiation. The 2 year overall survival and event-free survival for children older than 3 years were 89% and 78%, significantly higher than those younger than 3 years, 17% and 11%, respectively. Among those younger than 3 years, two were long term survivors and both received radiotherapy as part of the initial treatment, suggesting administering radiation earlier in the treatment course may be of benefit. A multi-institutional prospective study included a higher percentage of children younger than 3 years who received radiation (8 out of 15), and the disease free survival and overall survival rates were higher, compared to that from St. Jude. To further study the potential benefit and age cutoff of radiation in AT/RT, a phase III trial ACNS0333 by Children’s Oncology Group was carried out. Both standard and intensified chemotherapy regimens have been shown to be active in AT/RT.

The use of alkylating agents, high-dose methotrexate, or high dose chemotherapy followed by stem cell rescue, may be associated with improved survival. To determine the optimal adjuvant therapy for AT/RT, the Children’s Oncology Group conducted a prospective study, ACNS0333, which was recently closed in February 2014. This study was designed to determine whether surgery, intensive chemotherapy and early radiation improve survival compared to historical controls. In this study, children with post fossa tumors 6 months or older after induction chemotherapy were randomized to early radiation followed consolidative chemotherapy vs upfront consolidative chemotherapy and delayed radiation. Similarly, in supratentorial tumors, children 12 months or older were randomized to early vs. delay radiation after induction. Craniospinal radiation was administered in children with metastasis after chemotherapy and are at least 12 months of age. Neurotoxicity was closely monitored in the study. Results will be published in the future. http://www.childrensoncologygroup.org/

When administered, radiation therapy typically involves using a 3D conformal technique, targeting the operative-bed and residual tumor with and without cranial spinal radiation. Craniospinal radiation is typically reserved for those with disseminated disease.

Clinical outcome

Atypical teratoid/rhabdoid tumor is an extremely aggressive tumor. A recent Surveillance, Epidemiology, and End Result (SEER) analysis reported a median survival of 10 months. Median survival and event-free survival of children enrolled in the AT/RT registry were 17 and 10 months, respectively.

Future direction

Molecular targeted therapy has been an area of active research for AT/RT. It has been reported that in the absence of INI1, Cyclin D1 may drive rhabdoid tumor proliferation, bypassing the G1 cell cycle check point. Histone deacetylase (HDAC) inhibitors and Vitamin A analogs such as retinoids and retinoids have been shown to reduce Cyclin D1 expressions in cell culture, making them attractive agents for AT/RT.

IN1 has been implicated in the downstream regulation of the Aurora A gene transcription, suggesting the Aurora kinase pathway may be implicated in the pathogenesis of AT/RT. Aurora kinase inhibitors have been studied in clinical trials of other tumors. They may be reasonable candidates for AT/RT. Other pathways, such as the insulin-growth factor are also being investigated.

Choroid plexus carcinoma

Epidemiology

Choroid plexus tumors are rare tumors arising from the choroid plexus epithelium. They include three histologies, choroid plexus papilloma (WHO grade I), atypical choroid plexus papilloma (WHO grade II) and choroid plexus carcinoma (WHO grade III). All together, they account for 0.4-0.6% of all brain tumors. Choroid plexus tumors occur more frequently in children, comprising approximately 4% of all pediatric brain tumors. Up to 20% of these tumors occur during the first year of life. 20% to 40% of choroid plexus tumors are choroid plexus carcinomas.

Histopathology and molecular features

On gross pathology, choroid plexus carcinomas have a papillary or cauliflower-like appearance. They often show areas of hemorrhage and necrosis, with tumor invasion into the periventricular brain parenchyma. On histologic examination, these tumors are characterized by increased cell density, increased mitotic figures (>5 per 10 high power field), nuclear pleomorphism and necrosis. On immunohistochemistry, choroid plexus carcinomas are almost always positive for cytokeratin, focally positive for synaptophysin, GFAP, EMA, CD 44, and CA 19-9. They are less likely to stain positive for S-100 and transthyretin. Histologically, choroid plexus carcinomas and AT/RT have overlapping features. However, the majority of choroid plexus carcinomas stain positive for INI1, whereas nuclear staining in AT/RT is almost always absent. This is a helpful distinguishing feature.

Imaging characteristics

Choroid plexus tumors most commonly arise from the lateral ventricles (50%), followed by the fourth (40%) and the third ventricle (5%). Other locations are rare, including the cerebellum/pons, suprasellar region, brain parenchyma and the spine. On CT, choroid plexus tumors appear heterogeneous and isodense with calcifications and necrosis. On MRI, choroid plexus carcinomas show heterogeneous intensities on both T1 and T2, with irregular enhancement and edema. Flow voids are often seen reflecting the vascular nature of the tumor. Tumor hemorrhage and necrosis are commonly seen as well. On MR spectroscopy, choroid plexus carcinomas can be distinguished from choroid plexus papillomas by exhibiting lower levels of myoinositol and higher levels of choline.

Clinical presentation

Patients present with signs and symptoms of cerebrospinal fluid obstruction, leading to increased intracranial pressure and hydrocephalus. Infants may have increased head circumference, bulging fontanelles, separate sutures, strabismus, vomiting or delayed development. Older children and adults may present with headaches, nausea, vomiting, lethargy, seizures, neurologic deficits or behavioral changes. Choroid plexus carcinomas can metastasize to the spine, therefore imaging of the entire neuraxis and CSF cytology are highly recommended. Approximately two thirds of the tumors disseminate throughout the entire CSF space. Extranodal metastases may also occur.

Treatment options

Surgery

Surgery is the standard first line therapy for all choroid plexus carcinomas. Gross total resection is the most important predictor of outcome. However, it is only achievable in 40-50% of cases. A number of factors contribute to the difficulty in obtaining a complete resection, including young patient age, large tumor size and vascularity. Operating on choroid plexus carcinomas carries a high risk of intraoperative hemorrhage. Pre-operative angiography, often combined with embolization, is done to help facilitate a complete resection. In addition, pre-operative chemotherapy has also been used to reduce tumor size and vascularity. A retrospective analysis by Wrede et al. demonstrated that in patients with an initial subtotal resection, undergoing a second resection was associated with improved survival, compared with those who did not (overall survival 60% vs 30% at 2 years). This study underscores the importance of surgery in the overall management of this disease.

Chemotherapy

The role of adjuvant chemotherapy in
Ganglioglioma

Epidemiology

Gangliogliomas account for 0.4% of all CNS tumors, 1.3% of brain tumors. The most commonly affected areas are the temporal lobe and the cerebellum. The least affected area is the spinal cord. When the spine is involved, the cervical spine is the most common site. Up to 80% of cases occur during the first three decades of life. There is a slight preponderance in males.

Histopathology and molecular features

As its name suggests, gangliogliomas consist of a mixed population of ganglion and glial cells. Grading of gangliogliomas has typically been based on the characteristics of the glial component. In the current WHO classification, gangliogliomas are considered WHO grade 1. Anaplastic gangliogliomas are considered WHO grade III and account for 5% of gangliogliomas. Malignant transformation has been reported in about 10% of cases. The transformation is mostly attributed to the changes of the glial component. The rate of transformation among spinal gangliogliomas is unknown.

Imaging characteristics

Computed tomography is often performed during initial work-up, showing hypodense, or mixed hypodense/isodense, solid or partially cystic masses. Calcifications are seen in 10-50% of cases. On MRI, tumors are usually isointense or hypointense on T1-weighted images and hyperintense on T2-weighted images. Contrast enhancement is seen and may be nodular, rim-like or entirely solid. Cysts are seen in about 50% of the cases and may be associated with mural nodules.

Clinical presentation

For spine gangliogliomas, the most common presenting symptoms are back pain and extremity weakness. For brain gangliogliomas, the most common presenting symptom is chronic seizures, followed by neuro-ophthalmological findings, elevated ICP, and focal deficits. Gangliogliomas are highly epileptogenic.

Treatment options

Complete surgical resection is the treatment of choice, and is the single most important predictor of tumor control. There is no clear benefit of adjuvant radiotherapy after gross total resection. For those with subtotal resection or biopsy, the role of radiation and/or chemotherapy is controversial. In a retrospective review from University of California San Francisco (UCSF), the recurrence rate after subtotal resection was three times higher in those with highly anaplastic features, compared to those with moderate anaplastic features, suggesting a role for adjuvant treatment in this setting. Because gangliogliomas predominantly affect young individuals, the benefit of radiation must be carefully weighed against long term toxicities of radiation, especially its impact on neurocognition. In addition, some have expressed concern that malignant degeneration can occur after radiation for low grade gangliogliomas. Adjuvant radiation after a subtotal resection should be reserved only for those with a high risk of recurrence. For recurrent disease, surgical resection is still the first line therapy. Adjuvant radiation may be considered, especially in those with anaplastic transformation. Chemotherapy may be considered as well, although the agent of choice or the optimal duration is unclear.

Clinical outcome

Low grade gangliogliomas have favorable prognosis with 5 year overall survival over 90%. In a University of California Los Angeles (UCLA) series of 34 patients, including 25 low grade and 9 high grade tumors, progression free survival was 67% at 4 years, 77% after gross total resection and 51% after subtotal resection. Median time to progression was 14 months. Overall survival was 75%. Age, gender, tumor size, symptom duration, tumor grade, calcification, or enhancement had no impact on OS or PFS.

In a SEER analysis of 58 patients with anaplastic ganglioglioma, overall survival was 63% at 5 years and the median overall survival was 28.5 months. Uni-focal disease and surgery predicted better outcome. Adjuvant radiation was not associated with improved survival.

Hemangiopericytoma

Epidemiology

Hemangiopericytomas represent <1 % of all primary central nervous system tumors. Its incidence is about 1/50 of that of meningioma. The median age of onset is in the 40s. There is a slight male predominance.

Histopathology and molecular features

Hemangiopericytoma was first described as a variant of meningioma, hence the term angioblastic meningioma. In 1993, it became recognized as a distinct entity by the World Health Organization grading system. It is now

Outcome

Five-year overall survival is about 40-50%. Gross total resection is the most consistent predictor of survival.
commonly classified as WHO grade II, with an anaplastic variant classified as WHO grade III.\textsuperscript{25,26} Grossly, hemangiopericytomas are solitary and well circumscribed tumors.\textsuperscript{27} They often have grossly visible vascular structures. Brain invasion is seen in some.\textsuperscript{28} Histologically, hemangiopericytomas are rare, highly vascularized mesenchymal tumors. They develop from malignant transformation of pericytes, which are contractile spindle cells surrounding the walls of capillaries and post-capillary venules.\textsuperscript{35} Morphologically, hemangiopericytomas are remarkably similar to meningioma. To distinguish the two tumors, a number of immunohistochemical and genetic markers have been developed. They include EMA, claudin-1, 1p, 14q, NF2, and 4.1B.\textsuperscript{39} EMA and claudin-1 staining are strong and diffuse in meningiomas, but weak and patchy in hemangiopericytomas. Deletions such as 14q, 1p, NF2, and protein 4.1B are typical of meningiomas, but are rare in hemangiopericytomas.

**Imaging characteristics**

On CT, hemangiopericytomas are well demarcated, contrast enhancing lesions with dural attachment, often found in the parasagittal sinus and falxine regions. Angiography reveals extensive vasculature, often with dual cortical and meningeal supplies. On MRI, these tumors are iso- to hyperintense on T1 and iso to hypointense on T2 weighted images. They show bright and often heterogeneous enhancement with gadolinium. Imaging differentials include meningioma and hemangioblastoma. In contrast to meningioma, hemangiopericytomas have a more narrow-based attachment to dura. Hemangioblastomas are more frequently infratentorial.\textsuperscript{28}

**Clinical presentation**

Clinical presentation is largely dependent on lesion location. Patients may present with headache, seizures, focal weakness, visual changes, gait disturbances, or cognitive changes. Tumors infrequently involve the spine. In contrast to most primary brain tumors, hemangiopericytomas have a high propensity for extracranial metastasis. Common sites include bone, lung, liver and abdominal cavity.\textsuperscript{33} The incidence of metastases has been reported to be as high as 65% at 15 years.\textsuperscript{40} Therefore, it is important to perform staging work-up at the time of initial diagnosis and at recurrence.

**Treatment**

Surgery is the first line therapy for the treatment of hemangiopericytoma. Whenever feasible, gross total resection should be pursued. Resectability is largely dependent on tumor location. Because of the extreme vascular nature of the tumor, a major cause of operative mortality is uncontrolled bleeding.\textsuperscript{27} Reported rates of complete resection range from 30-70\%.\textsuperscript{35,36,44-42} Greater extent of resection has been associated with improved survival.\textsuperscript{21} With surgery alone, local recurrence rate has been reported to be as high as 90\%, and relapse can occur as early as 7 months after the initial treatment.\textsuperscript{23,43} Several retrospective series have shown that radiation plays an important role in preventing local recurrence. Both conventionally fractionated external beam radiotherapy and radiosurgery have been used in the post-operative setting.\textsuperscript{16,37,44,45}

A radiation dose response for hemangiopericytoma has been reported. In a retrospective review from the University of Pittsburgh, all patients received adjuvant stereotactic radiosurgery. 19\% of the lesions treated with a marginal dose ≥14 Gy developed an in-field recurrence/progression, whereas 50\% of the lesions receiving <14 Gy progressed. In multivariate analysis, a marginal dose ≥14 Gy was significantly associated with improved progression free survival (P=0.02).\textsuperscript{44} Similarly, in external beam series, Bastin et al. reported 14\% local recurrence rate for patients receiving more than 50 Gy, and 78\% for those receiving less than 45 Gy.\textsuperscript{37} Mayo Clinic reported no recurrence in patients treated with 51.56 Gy, and 88\% in those with <45 Gy.\textsuperscript{37,43} Based on this literature, a typical regimen is to deliver adjuvant radiation to 50-60 Gy in conventional fractionation to the operative bed and residual tumor. Figure 1 shows a case example. Radiosurgery can be used for small target volumes at a dose of 15 Gy or higher.

The importance of radiation therapy in preventing local recurrence has been well established. It has also been noted that radiation does not reduce the rate of distant metastasis. Whether radiation therapy can improve survival is unclear. Stessin et al. conducted a SEER analysis of 76 patients. They found that radiation was associated with improved cause-specific survival and, in particular, in those who underwent subtotal resection.\textsuperscript{41}

The role of chemotherapy in hemangiopericytoma is mostly limited to recurrent, surgery and radiation refractory tumors. Several regimens have been reported with modest efficacy, including cyclophosphamide, doxorubicin, and vincristine (CAV), alpha-interferon, ifosfamide, cisplatin and etoposide.\textsuperscript{46}

**Clinical outcome**

Median survival for patients with intracranial hemangiopericytoma is 13 years. Ten yr OS and DFS are 60-70\% and 20-30\%, respectively. Even after aggressive upfront treatment, about 50\% of patients develop recurrence. Median time to recurrence is about 5 years. Radiation is recommended after both gross total and subtotal resection.

---

**Figure 1.** A 27-year-old patient was diagnosed with an atypical hemangiopericytoma and baseline magnetic resonance imaging (MRI) in A). Subtotal resection was performed. The post-operative radiation planning MRI is shown in B), GTV outlined as surgical bed (green), a 0.5 cm expansion on the GTV to create the PTV 60 (sky blue), a 1.5 cm CTV applied to the GTV to give a CTV 54 (red) and a 0.5 cm PTV margin applied to the CTV 54 to give a PTV 54 (blue). This patient was treated with a two phase technique to a total of 60 Gy in 30 fractions and isodose lines shown in C). The patient’s tumor was controlled for 5 years with clean images as shown in D). At 5 years, a recurrent tumor nodule developed at the region of the cavernous sinus edge (yellow arrow) and this is where relative under-dosing occurred to keep the optic chiasm to a point maximum dose of 54 Gy. The patient is now on bevacizumab.
Pleomorphic xanthoastrocytoma

Epidemiology

Pleomorphic xanthoastrocytomas (PXA) comprise of <1% of primary brain tumors. It was first described by Kepes et al. in 1979. It was incorporated into the WHO classification in 1993.47-49 PXA is a tumor of children and young adults, with a median age of diagnosis of 20.5 years. It most commonly involves the temporal lobe. The tumor occurs equally in males and females.

Histopathology and molecular features

Pleomorphic xanthoastrocytomas is composed of astrocytes with pleomorphic nuclei and multinucleated giant cells. Historically, these tumors were classified as giant cell glioblastomas due to its morphology. However, patients with PXAs have much longer disease free survival and overall survival, compared to those with glioblastomas. It typically presents as WHO grade II tumors. Transformation into Grade III and IV disease can occur in 15-20% of cases.45,46 BRAF V600E mutation and homozygous deletion of CDKN2A (p16) have been reported in PXA. Their roles in tumorigenesis have not been clearly defined.51

Imaging characteristics

On CT, PXA appears hypodense and enhances with contrast. On T1-weighted MRI, PXA can have variable intensity and variable degree of enhancement with gadolinium. It is typically hyperintense on T2. The most typical appearance of a PXA is a partially calcified, cystic or solid lesion in the superficial temporal cortex involving the leptomeninges. A key feature differentiating PXA from pilocytic astrocytoma is the minimal or no enhancement of the cyst wall. Radiologic differential diagnoses include meningioma, dysembryonc neuroectodermal tumor (DNET), ganglioglioma, and pilocytic astrocytoma.52

Clinical presentation

The most common presenting symptom is seizure, followed by headaches, nausea, vomiting consistent with increased intracranial pressure, or focal neurologic deficits.

Treatment options

Maximal safe surgical resection is the first line therapy for all patients. Greater extent of surgical resection has consistently been associated with improved survival.48,49,51 After gross total resection, adjuvant therapy is generally not recommended. Local recurrence can occur in 15-20% of cases after surgical resection. Anaplastic transformation has been reported at the time of recurrence.51

The role of adjuvant chemotherapy and radiation is not well established in PXA. Pahapill suggested a possible benefit of radiation in tumors without necrosis.50 McCaulay et al. reported no difference in overall survival among those treated or not treated with radiation, but the incidence of recurrence was slightly higher among those not receiving radiation (42% vs 30%).54 In a SEER analysis by Perkins et al., the use of radiation was associated with worse survival. However, a significantly higher percentage (55%) of grade III and IV tumors received radiation, whereas only 10% of patients with low grade tumors received radiation. Since their analysis did not include grade as a variable due to missing information among subjects, interpretation of this result is difficult. While there is no clear benefit of radiation, it is often used for grade III-IV tumor, recurrent disease or after subtotal resection.48

Clinical outcome

In a SEER analysis of 214 patients, five and ten year overall survival rates were 75% and 67%, respectively. For patients with WHO grade IV tumors, median survival was 45 months. Male gender, increasing age, high grade and incomplete surgical resection were associated with worse prognosis. PXA patients had worse survival than those with pilocytic astrocytoma and oligodendroglioma, but better outcomes compared to ependymoma and glioblastoma patients.48

Conclusions

Given the rarity of these primary central nervous system tumors, it is highly unlikely that large scale prospective trials evaluating different treatment approaches will be completed within a reasonable timeframe. Currently, one has to resort to small or fairsized retrospective studies to gain knowledge of the clinical, pathologic, and therapeutic aspects of these tumors to guide clinical practice. Collaborative research through rare tumor network (http://www.rarecancer.net/), which can potentially collect information from a large number of patients from multiple cancer centers or population databases, may be the best means to enhance better understanding of the behaviors of these rare central nervous system tumors and to determine the best treatment strategies.

References


[ Rare Tumors 2014; 6:5449]